SCHEDULE 13G/A: BlackRock Discloses 8.1% Stake in IDEAYA Biosciences
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.1% of IDEAYA Biosciences Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 4 to Schedule 13G, detailing its beneficial ownership in IDEAYA BIOSCIENCES INC.
- As of March 31, 2025, BlackRock, Inc. beneficially owns 7,130,507 shares of IDEAYA BIOSCIENCES INC. common stock.
- This ownership represents 8.1% of the total outstanding common stock of IDEAYA BIOSCIENCES INC.
- BlackRock, Inc. holds sole voting power over 7,037,676 shares and sole dispositive power over 7,130,507 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a neutral, factual disclosure of beneficial ownership. The presence of a large institutional investor like BlackRock holding a significant stake (8.1%) can be seen as a positive signal of confidence, but the document itself does not contain performance or strategic updates to warrant a higher score. It's an expected regulatory filing.
Positives
- BlackRock, Inc., a prominent institutional investor, holds a significant 8.1% stake, which can be interpreted as a signal of institutional confidence in IDEAYA BIOSCIENCES INC.
- The filing explicitly states that the shares are held in the ordinary course of business, indicating a passive investment strategy rather than an activist intent.
Future Outlook
NA
Industry Context
This filing reflects a significant institutional investment in the biotechnology sector, specifically in IDEAYA BIOSCIENCES INC., by one of the world's largest asset managers, BlackRock. Such large holdings by major investment firms are common across various industries, including biotech, where long-term growth potential is often sought.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by BlackRock may influence investor perception and potentially stock price due to perceived institutional confidence.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previous Power of Attorney, which was subsequently revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 2025-04-17 | Date of filing and signature of the Schedule 13G Amendment No. 4. |
Keywords
BlackRock, IDEAYA BIOSCIENCES INC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.